Induction of cytotoxic T-lymphocyte responses
AssigneeIDEC Pharmaceuticals Corporation
InventorsSyamal Raychaudhuri, William H. Rastetter
Life of this patent
Estimating the term…
Abstract
Methods and compositions useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the antigen to which the CTL response is desired and providing an antigen formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This antigen formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.
Claims35
A method of treating a human infected with HIV virus, comprising administering a composition comprising an HIV antigen mixed with a microfluidized antigen formulation comprising:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation lacking an immunostimulating peptide component, and being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human infected with malaria, comprising administering a composition comprising a malaria-associated antigen mixed with a microfluidized antigen formulation comprising:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation lacking an immunostimulating peptide component, and being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human infected with influenza, comprising administering a composition comprising an influenza-associated antigen mixed with a microfluidized antigen formulation comprising:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation lacking an immunostimulating peptide component, and being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human infected with hepatitis, comprising administering a composition comprising a hepatitis-associated antigen mixed with a microfluidized formulation comprising:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation lacking an immunostimulating peptide component, and being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human having a cancer, comprising administering a composition comprising a cancer-associated antigen mixed with a microfluidized antigen formulation comprising:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation lacking an immunostimulating peptide component, and being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human infected with herpes virus, comprising administering a composition comprising a herpes antigen mixed with a microfluidized antigen formulation comprising:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation lacking an immunostimulating peptide component, and being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human infected with respiratory syncytial virus, comprising administering a composition comprising a respiratory syncytial antigen mixed with a microfluidized antigen formulation comprising:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation lacking an immunostimulating peptide component, and being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method for inducing a cytotoxic T-lymphocyte response in a human, comprising the steps of:
- administering a mixture of an antigen mixed with a microfluidized antigen formulation consisting essentially of two of:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation being formulated as a stable oil-in-water emulsion;
- wherein said mixture is administered to said human or animal in an amount sufficient to induce a cytotoxic T-lymphocyte response in said human or animal.
A method of treating a human infected with HIV virus, comprising administering a composition comprising an HIV antigen mixed with a microfluidized antigen formulation consisting essentially of two of:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human having malaria, comprising administering a composition comprising a malaria-associated antigen mixed with a microfluidized antigen formulation consisting essentially of two of:
- (a) stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human infected with influenza, comprising administering a composition comprising an influenza-associated antigen mixed with a microfluidized antigen formulation consisting essentially of two of:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human having hepatitis, comprising administering a composition comprising a hepatitis-associated antigen mixed with a microfluidized antigen formulation consisting essentially of two of:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human having a cancer, comprising administering a composition comprising a cancer-associated antigen mixed with a microfluidized antigen formulation consisting essentially of two of:
- (a) a stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human infected with herpes virus, comprising administering a composition comprising a herpes antigen mixed with a microfluidized antigen formulation consisting essentially of two of:
- (a) stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
A method of treating a human infected with respiratory syncytial virus, comprising administering a respiratory syncytial antigen mixed with a microfluidized antigen formulation consisting essentially of two of:
- (a) stabilizing detergent,
- (b) a micelle-forming agent, and
- (c) a biodegradable and biocompatible oil,
- said antigen formulation being formulated as a stable oil-in-water emulsion;
- wherein said composition is administered to said patient in an amount sufficient to induce a cytotoxic T-lymphocyte response in said patient.
Dependencies are inferred from the claim text.